BioSpace News Archive

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to treat refractory solid tumors.

Accuray Incorporated announced that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation delivered with the TomoTherapy® System.

Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Carla Poulson has joined the company as Chief Human Resources Officer.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its preliminary unaudited fourth quarter and full year 2020 revenues.

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement,

Dosing in Phase 1 Study in Subjects with PD-L1-Positive Cancers Expected to Start in 2Q21

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million.

Petros Pharmaceuticals (Nasdaq: PTPI) today announces that its president and chief commercial officer Fady Boctor will present at NobleCon17 - Noble Capital Markets’ Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 9:00 AM ET in Track 2. A high-definition, video webcast of the presentation will be available the following day on the Company’s website www.petrospharma.com, and as part of a complete catalog of presentations to

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer.

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it plans to host a virtual event on Tuesday, January 26, 2021 from 8 to 10 a.m. ET to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.